See more : Energous Corporation (0IH3.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sandoz Group AG (SDZNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sandoz Group AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Stelux Holdings International Limited (0084.HK) Income Statement Analysis – Financial Results
- Silverton Energy, Inc. (SLTN) Income Statement Analysis – Financial Results
- Kilroy Realty Corporation (KRC) Income Statement Analysis – Financial Results
- Plus500 Ltd. (PLUS.L) Income Statement Analysis – Financial Results
- Viratech Corp. (VIRA) Income Statement Analysis – Financial Results
Sandoz Group AG (SDZNY)
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 9.98B | 8.86B | 8.79B | 9.04B |
| Cost of Revenue | 5.42B | 4.71B | 4.64B | 4.88B |
| Gross Profit | 4.56B | 4.15B | 4.15B | 4.16B |
| Gross Profit Ratio | 45.74% | 46.87% | 47.20% | 45.99% |
| Research & Development | 926.00M | 795.57M | 832.90M | 819.41M |
| General & Administrative | 0.00 | 22.50K | 0.00 | 0.00 |
| Selling & Marketing | 2.39B | 0.00 | 0.00 | 0.00 |
| SG&A | 2.39B | 22.50K | 1.94B | 2.00B |
| Other Expenses | 874.00M | 8.60M | 6.40M | 5.63M |
| Operating Expenses | 4.19B | 22.50K | 2.77B | 2.81B |
| Cost & Expenses | 9.60B | 22.50K | 7.41B | 7.69B |
| Interest Income | 31.00M | 7.64M | 4.57M | 2.82M |
| Interest Expense | 202.00M | 84.05M | 61.26M | 70.40M |
| Depreciation & Amortization | 525.00M | 437.42M | 447.08M | 650.46M |
| EBITDA | 857.00M | 1.68B | 1.83B | 1.99B |
| EBITDA Ratio | 8.59% | 0.00% | 20.77% | 22.03% |
| Operating Income | 375.00M | -22.50K | 1.38B | 1.34B |
| Operating Income Ratio | 3.76% | 0.00% | 15.69% | 14.83% |
| Total Other Income/Expenses | -245.00M | -137.00M | -179.20M | -677.68M |
| Income Before Tax | 130.00M | -22.50K | 1.20B | 662.66M |
| Income Before Tax Ratio | 1.30% | 0.00% | 13.65% | 7.33% |
| Income Tax Expense | 50.00M | 361.00 | 368.45M | 227.14M |
| Net Income | 77.00M | -22.86K | 830.15M | 433.64M |
| Net Income Ratio | 0.77% | 0.00% | 9.44% | 4.80% |
| EPS | 0.18 | 0.00 | 1.93 | 1.01 |
| EPS Diluted | 0.18 | 0.00 | 1.93 | 1.01 |
| Weighted Avg Shares Out | 429.90M | 431.00M | 431.00M | 431.00M |
| Weighted Avg Shares Out (Dil) | 431.20M | 431.00M | 431.00M | 431.00M |
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (Sandoz)...
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalmology portfolio and increases access for patients Expected to be key biosimilar growth driver in...
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG (OTCQX:SDZNY) Q2 2024 Earnings Conference Call August 8, 2024 3:00 AM ET Company Participants Karen King - Global Head, Investor Relations Richard Saynor - Chief Executive Officer Remco Steenbergen - Chief Financial Officer Conference Call Participants James...
Sandoz reports second-quarter sales and half-year 2024 results
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprint Pyzchiva®...
3 Spinoff Stocks You Should Buy Now: July 2024
Stock spinoffs remain popular with companies wanting to unlock shareholder value. By creating spinoff stocks that will trade independently on the market, corporations believe they can narrow their focus to core operations while the newly public company doesn't get lost in the shuffle of...
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicine FDA granted provisional determination...
Source: https://incomestatements.info
Category: Stock Reports